BioGeneration Ventures logo

BioGeneration Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series A

Avidicure logo
Avidicure

Biotechnology • Multifunctional Antibodies

V-Bio Ventures logo
Kurma Partners logo
EQT Life Sciences logo
Curie Capital logo

Avidicure is a biotechnology company developing innovative multifunctional antibodies for oncology, focusing on non-small cell lung cancer.

Seed
$50M
04/24/2025
Article
RhyGaze logo
RhyGaze

Gene therapy • Retinal diseases

GV logo
Novartis logo
F-Prime Capital logo
BioGeneration Ventures logo

RhyGaze is a biotechnology company developing gene therapies for vision restoration in retinal diseases.

Series A
$86M
01/10/2025
Article
Citryll logo
Citryll

Biotech • NET-targeting

Forbion logo
Novartis logo
Johnson & Johnson Innovation logo
Seventure Partners logo

Citryll is a biotech company developing therapies for immune-mediated inflammatory diseases, focusing on a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).

Series B
$89.8M
12/09/2024
Article
Kivu Bioscience logo
Kivu Bioscience

Biotech • Antibody-drug conjugates

Novo Holdings logo
Red Tree Venture Capital logo
M Ventures logo
HealthCap logo

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates for cancer treatment.

Series A
$92M
10/28/2024
Article
VectorY logo
VectorY

Biotech • Vectorized Antibody Program

EQT Life Sciences logo
MRL Ventures Fund logo
Insight Partners logo
Forbion Ventures logo

VectorY Therapeutics is a biotech company focused on developing vectorized antibody therapies for neurodegenerative diseases, with a lead program targeting Amyotrophic Lateral Sclerosis (ALS).

Series A
$137.8M
11/13/2023
Article
Tessellate BIO logo
Tessellate BIO

Precision oncology medicines • DNA damage response

Forbion logo
BioGeneration Ventures logo

Tessellate BIO is a preclinical stage biotechnology company that develops precision oncology medicines targeting the DNA damage response and cancers relying on Alternative Lengthening of Telomeres (ALT).

Seed
$8.4M
10/17/2023
Article